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Abstract
Background: India has a high burden of drug resistant TB, although there are few data on XDR-TB. Although XDR-TB has
existed previously in India, the definition has not been widely applied, and surveillance using second line drug susceptibility
testing has not been performed. Our objective was to analyze clinical and demographic risk factors associated with isolation
of MDR and XDR TB as compared to susceptible controls, at a tertiary center.
Methodology/Findings: Retrospective chart review based on positive cultures isolated in a high volume mycobacteriology
laboratory between 2002 and 2007. 47 XDR, 30 MDR and 117 susceptible controls were examined. Drug resistant cases were
less likely to be extrapulmonary, and had received more previous treatment regimens. Significant risk factors for XDR-TB
included residence outside the local state (OR 7.43, 3.07-18.0) and care costs subsidized (OR 0.23, 0.097-0.54) in bivariate
analysis and previous use of a fluoroquinolone and injectable agent (other than streptomycin) (OR 7.00, 95% C.I. 1.14-43.03)
and an initial treatment regimen which did not follow national guidelines (OR 5.68, 1.24-25.96) in multivariate analysis.
Cavitation and HIV did not influence drug resistance.
Conclusions/Significance: There is significant selection bias in the sample available. Selection pressure from previous
treatment and an inadequate initial regimen increases risk of drug resistance. Local patients and those requiring financial
subsidies may be at lower risk of XDR-TB.
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Introduction
India has the greatest burden of Tuberculosis (TB) disease in the
world, with 1.8 million new cases annually and an estimated
prevalence of 3.8 million bacteriologically proven cases in 2000.[1]
Annual loss to thecountry’s economy due to TB isgreater thanUS$3
billion.[2]
Multidrug resistant TB (MDR-TB) is defined as resistance to the
two most important first-line drug treatments, isoniazid and
rifampicin. Extensively drug resistant TB (XDR-TB) is resistant to
these first line agents, as well as to at least one fluoroquinolone and at
least one injectable agent.[3] This phenotype emerges from MDR-
TB, with the acquisition of further drug resistance mutations,and was
first described in the United States[4], followed by the Tugela Ferry
outbreak.[5] XDR-TB is associated with a significantly worse clinical
outcome,[6,7] and risk factors for poor treatment response have been
defined.[8] MDR and XDR represent distinct phenotypes and are
considered separately in this paper and other publications. Primary
drug resistance is defined as cases which have not be previously
treated, and secondary drug resistance occurs in pre-treated patients.
The objective of our study was to describe the clinical and
demographic risk factors associated with the isolation of XDR-TB
in a tertiary hospital laboratory in South India. We surveyed drug
susceptibility test (DST) results between 2002 and 2007 and
identified isolates meeting the criteria for MDR and XDR-TB. We
retrospectively reviewed these cases and compared them to
controls with susceptible disease.
Methods
Ethics Statement
The study was approved by the ethics review board of the
Christian Medical College Vellore in February 2008. Patient
consent was not obtained because data were analyzed anony-
mously.
DST Testing
All DST was performed by the mycobacteriology section of the
Clinical Microbiology Department at the Christian Medical
College Vellore, which is externally accredited by the Revised
National Tuberculosis Control Program and the Central Tuber-
culosis Division, Ministry of Health, Government of India. DST
for first-line (isoniazid, rifampicin, ethambutol and streptomycin)
and second line (ciprofloxacin, ethionamide, capreomycin and
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method (MIC) for all drugs except streptomycin, in which the
resistance ratio method was used. During 2007, the DST method
for first line drugs was changed to the 1% proportion method.
Drugs were procured from Sigma (USA), and for each batch of
DST, a sensitive strain of H37Rv was used as a control.
Case Definitions
Results for indicator drugs Isoniazid, Rifampicin, Ciprofloxacin
(fluoroquinolone class) and Capreomycin (injectable class) were
used in the definition. Isolates resistant to both Isoniazid and
Rifampicin only were defined as MDR, and isolates resistant to all
four of these drugs were defined as XDR.
Case Inclusion
The Mycobacteriology laboratory DST registers between 2002
and 2007 were reviewed. Inclusion in the study was limited to
specimens growing Mycobacterium tuberculosis which were tested for
first and second line DST by request of the physician, and which
were available for our evaluation (ordered from the department of
Medicine or from TB clinic). After isolates were identified from the
laboratory register, clinical information was sought. See Figure 1
for a summary of recruitment. There were no standard criteria for
referral for DST.
Between2002and2006, allavailable DSTresultswere considered.
Control isolates were susceptible to all tested drugs. In 2007, the
number of DST studies performed was much higher, so for this year,
susceptible controls were selected randomly (Microsoft Excel), in a
ratio of 3 susceptible controls for each MDR and XDR case.
Population
The Christian Medical College Vellore is a 2200 bed tertiary
referral hospital in Vellore, Tamil Nadu. Tamil Nadu has a TB
case detection rate of 131/100,000 per year.[2] Most TB patients
assessed have been previously seen or treated. Culture and DST is
not paid for by the government TB control program in India.
Analysis
Predefined risk factors associated with drug resistance were
included in a case report form, which was piloted on 10 patient
charts. Clinical, demographic and WHO defined[9] risk factors
were included based on previous literature, and drug treatment
history was extracted. The following risk factors were examined:
HIV infection[10] (tested in 134/203 (66%) cases), socioeconomic
status[11] (as approximated by the provision of subsidy for the cost
of care), gender, age category, cigarette use, alcohol use[1], site of
TB disease[1], diabetes[1], residence outside of the state (referral
patients) [12], cavitation on CXR[11], number of different
previous treatment regimens[13], previous use of injectable agents
and fluoroquinolones[13] and adequacy of initial treatment
(defined as whether or not the initial treatment regimen followed
the regimen outlined by the national treatment program for new
smear positive TB patients[2]). Descriptors and risk factors were
compared using independent samples T-test. Bivariate and
multivariable logistic regression was performed to compare
MDR and XDR cases to susceptible cases (SPSS 13.0).
Results
1544 cultures with first and second line DST were available
between 2002 and 2007 (Figure 1). Among these, 532 were
ordered by Medicine units or TB clinic, 382 of which were unique
(one specimen per patient). Of these, 188 had incomplete clinical
information available, or did not have complete DST and thus
could not be assigned to one resistance category, leaving 194
results available for complete analysis. Of these, 47 patients had
Figure 1. Recruitment.
doi:10.1371/journal.pone.0009527.g001
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was collected by combining the entire population of susceptible
cases from 2002–2006 with the randomly selected susceptible
group from 2007. 117 patients were used as susceptible controls.
The 117 Susceptible cases were 20.5% females (24/117), with a
mean age of 42 years (SD 14.5) (see Table 1). Twenty three were
only extrapulmonary cases (20.5%). Eighty eight were tested for
HIV, among which 25 were HIV infected (28.4%). Mean number
of different treatment regimens prior to culture was 2.5 (SD 1.7).
Thirty three had cavitation on CXR (29.2%), and 9 (8.5%) had
received treatment with both an injectable agent (other than
streptomycin) and a fluoroquinolone.
The 30 MDR-TB cases were 26.7% females (8/30), with a
mean age of 37.3 years (SD 14.2). Only one was extrapulmonary
disease (3.3%, p=0.002 vs susceptibles). Fourteen were tested for
HIV, among which 1 was HIV infected (7.2%, p=0.092 vs
susceptibles). Mean number of different treatment regimens prior
to culture was 4.7 (p,0.001 vs susceptibles). Thirteen (41.9%,
p=0.17 vs susceptibles) had cavitation on CXR and 19 (63.3%,
p,0.001 vs susceptibles) had received treatment with both an
injectable agent (other than streptomycin) and a fluoroquinolone.
All cases had been previously treated at least once.
The 47 XDR-TB cases were 29.2% females (14/47), with a
mean age of 37.0 years (SD 12.5). Only 3 were extrapulmonary
cases (10.3%, p=0.001 vs susceptibles). All were tested for HIV,
among which 3 were infected (6.4%, p=0.049 vs susceptibles).
Mean number of different treatment regimens prior to culture was
4.2 (p,0.001 vs susceptibles). Twenty-two (46.8%, p=0.048 vs
susceptibles) had cavitation on CXR and 28 (62.2%, p,0.001 vs
susceptibles) had received treatment with both an injectable agent
(other than streptomycin) and a fluoroquinolone. All cases had
been previously treated at least once.
In the bivariate logistic regression analysis, three variables were
associated with MDR as compared to susceptible TB (see Table 2).
Previous treatment with an injectable and fluoroquinolone was
strongly associated with MDR (OR 18.62, 95% C.I. 6.78–51.06).
Smoking was negatively associated with MDR (OR 0.23, 95% C.I.
0.063–0.81) as was alcohol use (OR 0.11, 95% C.I. 0.014–0.82).
Residence outside the state of Tamil Nadu demonstrated a trend
towards association (OR 2.25, 95% C.I. 0.98–5.15).
A multivariable regression was created using the following
variables, considered either statistically or clinically significant:
smoking, alcohol, HIV, residence outside Tamil Nadu state,
extrapulmonary TB, costs of care subsidy, cavitation on CXR,
number of previous treatment regimens, previous treatment with a
fluoroquinolone and an injectable agent, and if first drug
treatment regimen followed national guidelines (see Table 3)
None of these were significantly associated with MDR-TB.
Table 1. Description of Cases.
Susceptible MDR XDR
Total Cases
N=194
117 30 47
Mean age
N=194
42.7+/214.5 37.3+/214.2
(p=0.066 vs Susc)
37.0+/212.5
(p=0.020 vs Susc)
Female
N=194
24/117 (20.5%) 8/30 (26.7%)
(p=0.47 vs Susc)
14/47 (29.8%)
(p=0.21 vs Susc)
Only Extrapulmonary TB
N=190
23/113 (20.5%) 1/30 (3.3%)
(p=0.002 vs Susc)
3/29 (10.3%)
(p=0.001 vs Susc)
HIV Infected*
N=131
25/88 (28.4%) 1/14 (7.2%)
(p=0.092 vs Susc)
3/47 (6.4%)
(p=0.049 vs Susc)
Mean number of difference treatment regimens before culture
N=183
2.5+/21.7 4.7+/21.7
(p,0.001 vs Susc)
4.2+/22.0
(p,0.001 vs Susc)
Previous treatment with a quinolone and injectable agent (other than streptomycin)
N=181
9/106 (8.5%) 19/30 (63.3%)
(p,0.001 vs Susc)
28/45 (62.2%)
(p,0.001 vs Susc)
Cavity present on CXR
N=185
33/113 (29.2%) 13/31 (41.9%)
(p=0.17 vs Susc)
22/47 (46.8%)
(p=0.048 vs Susc)
*More than 20% data unavailable.
doi:10.1371/journal.pone.0009527.t001
Table 2. Bivariate Analysis: Risk factors for MDR.
Risk factor
Odds Ratio
for MDR 95% C.I.
Age Category
Age ,21 reference
Age 21–30 0.78 0.12–5.34
Age 31–40 0.12 0.014–1.04
Age 41–50 0.60 0.079–4.54
Age .50 0.27 0.038–1.92
Female Sex 1.41 0.56–3.56
HIV infection* 0.19 0.024–1.56
Smoking 0.23 0.063–0.81
Alcohol use 0.11 0.014–0.82
Diabetes* 0.90 0.33–2.45
Residence outside Tamil Nadu state 2.25 0.98–5.15
Care costs subsidized 0.79 0.33–1.89
Initial treatment regimen did not follow national
guidelines
1.6 0.67–4.00
Previous treatment with a fluoroquinolone and
an injectable agent (other than streptomycin)
18.62 6.78–51.06
CXR shows cavity 1.78 0.78–4.09
Number of different treatment regimens 1.89 1.45–2.45
Extrapulmonary TB 0.14 0.017–1.04
*More than 20% data unavailable.
doi:10.1371/journal.pone.0009527.t002
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associated with XDR as compared to susceptible TB (see Table 3):
previous treatment with an injectable and fluoroquinolone (OR
17.75, 95% C.I. 7.14–44.14), residence outside the state of Tamil
Nadu (OR 7.43. 95% C.I. 3.07–18.00) and an initial treatment
regimen that did not follow national guidelines (OR 5.85, 95%
C.I. 2.53–13.52) were positively associated with XDR. Alcohol use
(OR 0.21, 95% C.I. 0.060–0.74), extrapulmonary TB (OR 0.27,
95% C.I. 0.076–0.94) and cost of care subsidized (OR 0.23, 95%
C.I. 0.097–0.54) were negatively associated with XDR.
A multivariable regression was created using the same variables
as above (see Table 4). Two variables were independently
associated with XDR-TB: previous treatment with a fluoroquin-
olone and an injectable agent (other than streptomycin) (OR 7.00,
95% C.I. 1.14–43.03), and an initial treatment regimen which did
not follow national guidelines (OR 5.68, 95% C.I. 1.24–25.96).
The most common deviation from national treatment guidelines
was the use of correct drugs for a duration longer than six months.
Discussion
We have undertaken a retrospective review of risk factors
associated with isolation of MDR and XDR as compared to
susceptible TB in a tertiary care referral center in India, the first
study to do so to date. Our study population is not representative
of TB patients in India due to selection bias, referral bias, and
selective testing bias. For this reason, we do not report a
prevalence rate of XDR-TB.
A group of 141 patients did not have enough DST data to be
classified into a resistance category, and were excluded from
analysis. In addition, only a single fluroquinolone and one
injectable agent were tested. Thus, XDR patients infected with
strains resistant to fluoroquinolones or injectable agents other than
those tested could be misclassified as MDR or drug-susceptible
TB. Due to our retrospective design, some of the variables
examined were inconsistently recorded or missing.
Our sample size of drug resistant isolates is small, although we
were able to screen a large number of isolates. Second line drug
susceptibility testing is not well standardized, so we cannot refer to
a standard laboratory method to corroborate our fluoroquinolone
or injectable susceptibility results.
We detected no primary drug resistance in our highly selected
population. Primary drug resistance is known to be uncommon in
India.
Nine surveys of TB drug resistance have been done in India
between 1997 and 2006. Primary MDR-TB was reported in
between 0.5 and 3.4% (9 studies), and secondary MDR-TB was
17.2% (1 study).[10] These incidence rates are similar to global
estimates of 2.9% and 15.3% respectively. However, since
retreatment cases represent 13.7% of notified cases in India, the
total burden of drug resistant TB is very high, with an estimate
that 110,132 new MDR-TB cases emerged in India in 2006, [10]
the most cases of any country.[14]
Although XDR-TB has existed previously in India[15], the
recent definition has not been widely applied, and community-
based surveillance has not be performed. Second line drugs are
widely available in the private sector, where most Indian TB
patients seek care.[16] However, drug susceptibility testing is not
widely available, although, the expectation is that there is a large
burden of resistant TB that will be uncovered with the wider
availability of culture laboratories proposed by the national TB
control program.[1]
XDR-TB has been described from 55 countries, and in all
world regions.[14] The first report of XDR-TB from India
surveyed 3,904 specimens, and thirty three cases met the definition
of XDR-TB, representing 8% of all MDR-TB cases.[17] Five
among 68 MDR isolates from Lucknow met the definition for
XDR.[18] Among 66 MDR patients on treatment, one had XDR-
TB, and two developed an XDR phenotype during treatment.[19]
In a fourth report, 54 HIV infected TB suspects were investigated
and four met the criteria for XDR-TB, and all died with 2.6
months of diagnosis.[20]
In a prospective study of 130 MDR and 130 drug susceptible
TB patients at a tertiary referral center in Delhi, a multivariate
model showed poor compliance, greater than one cavity, and
HLA DRB1*14 allele were associated with MDR.[11] In a
prospective study of 251 TB patients in Pune, 52 MDR cases were
identified, 36 (69.2%) of whom had a history of treatment default,
and 11 (21.2%) of whom were relapse cases.[21] The most
important reason for treatment default among MDR cases was
Table 3. Bivariate Analysis: Risk factors for XDR.
Risk factor
Odds Ratio
for XDR 95% C.I.
Age Category (years)
Age ,21 reference
Age 21–30 1.04 0.16–6.97
Age 31–40 0.49 0.072–3.27
Age 41–50 0.90 0.13–6.46
Age .50 0.31 0.044–2.15
Female Sex 1.64 0.76–3.55
HIV infection* 0.29 0.081–1.05
Smoking 0.43 0.18–1.03
Alcohol use 0.21 0.060–0.74
Diabetes* 0.82 0.35–1.91
Residence outside Tamil Nadu state 7.43 3.07–18.0
Care costs subsidized 0.23 0.097–0.54
Initial treatment regimen did not follow
national guidelines
5.85 2.53–13.52
Previous treatment with a fluoroquinolone and
an injectable agent (other than streptomycin)
17.75 7.14–44.14
CXR shows cavity 1.78 0.78–4.09
Number of different treatment regimens 1.60 1.29–1.98
Extrapulmonary TB 0.27 0.076–0.94
*More than 20% data unavailable.
doi:10.1371/journal.pone.0009527.t003
Table 4. Multivariate Analysis: Risk factors for XDR.
Risk Factor
Odds Ratio
for XDR 95% C.I.
Previous treatment with a fluoroquinolone and
an injectable agent (other than streptomycin)
7.00 1.14–43.03
Initial treatment regimen did not follow
national guidelines
5.68 1.24–25.96
Including smoking, alcohol, HIV, TN state, payment, regimen 1 adequate,
extrapulmonary TB, cavitary, number of regimens, previous treatment with
fluoroquinolone and injectable.
Only significant associations shown.
Model based on 69 cases with complete data.
doi:10.1371/journal.pone.0009527.t004
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symptom relief (8/36) and cost (2/36).
We report that previous use of both a fluoroquinolone and an
injectable agent (other than streptomycin) is associated with XDR,
which is expected since these agents may select for resistance when
used for second line TB treatment.[22] Referral patients from
outside the state of Tamil Nadu may be associated with drug
resistance. The referral bias of poor treatment responders from
different geographical area in India to our hospital is the best
explanation for this association.
Our data suggests that patients who cannot afford to pay for
their TB treatment may be less associated with the isolation of
XDR. One possibility for this observation is that these patients are
more likely to receive first line treatment in the national TB
control program (because they cannot afford private medical care),
which is associated with higher adherence rates.[23] It is possible
that these patients may not have been able to afford second line
treatment. However, the possibility that poorer patients with XDR
TB are less likely to come to the referral hospital or be fully
investigated microbiologically cannot be excluded.
Our patients with drug resistant TB had received up to 10
different treatment regimens prior to submitting the positive
culture. Drug resistant patients in our study had a greater number
of previous regimens than susceptible patients, as has been also
shown among XDR cases in Peru.[13]
Our data suggests that the an inadequate initial drug regimen
may be associated with the development of XDR, but with the
limitations of our design we cannot make this conclusion.
Our data suggests no association between HIV infection and
drug resistance, although because only 67.5% of patients in our
study were tested for HIV, we cannot make a conclusion on this.
Larger studies in Latvia and Donetsk Oblast have suggested an
association between HIV and MDR-TB, [10] and in the United
States, HIV was significantly more common among XDR cases as
compared to drug susceptible cases.[24] With an overall HIV
prevalence of less than 1%, India may not yet have enough HIV
cases to experience a significant overlap between the HIV and
drug resistant TB epidemics. During our study period, most
patients with HIV were not on antiretroviral treatment, and it is
probable that co-infected patients succumbed to the disease before
being identified and treated as MDR or XDR-TB.
We found that smoking and alcohol may be associated with a
lower risk of MDR-TB, and alcohol use may be associated with a
lower risk of XDR-TB. This finding may be biased by the loss of
individuals with these risk factors due to a generally poor state of
health or socio-economic status causing early death after
developing resistant TB, prior to submitting a specimen for
culture.
A decision must be made by a clinician to request a drug
susceptibility test from a TB patient. At our center, the decision to
order such testing is up to individual clinicians, based on medical
as well as economic factors, as this test may not be affordable to
the patient. The identification of clinical risk factors may help the
clinician decide when to request the test. According to the national
TB control program, DST should be performed on patients taking
category II treatment who remain smear positive after the fourth
month of treatment.[25] However, this strategy is a necessary
balance between operational considerations and early diagnosis,
and will provide delayed results for many cases with primary or
acquired drug resistance.
The development of drug resistance in TB in India is the result
of a complex web of biomedical, socio-cultural and behavioral
interactions,[26] and the reporting of individual risk factors is an
oversimplification. Health care worker ignorance, the wide misuse
of TB drugs, lack of laboratory standardization and delay in
laboratory results all contribute to the emergence of drug
resistance.[27]
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